ARTICLE | Clinical News
Aviptadil: Phase II data
May 26, 2008 7:00 AM UTC
In the Phase II AVICUTE trial in 20 patients, compared with baseline, a single 100 µg dose of Aviptadil significantly reduced pulmonary artery pressure by 5.0% and pulmonary vascular resistance by 7.8...